Global Single-use Bioreactors Market

1 INTRODUCTION OF GLOBAL SINGLE-USE BIOREACTORSMARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL SINGLE-USE BIOREACTORSMARKETOUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework

5 GLOBAL SINGLE-USE BIOREACTORS MARKET, BY APPLICATION
5.1 Research & Development
5.2 Process Development
5.3 Bio production

6 GLOBAL SINGLE-USE BIOREACTORS MARKET, BY TYPE OF CELL
6.1 Mammalian Cells
6.2 Bacterial Cells
6.3 Yeast Cells
6.4 Other Cells

7 GLOBAL SINGLE-USE BIOREACTORS MARKET, BY END USER
7.1 Biopharmaceutical Manufacturers
7.2 R&D Departments

8 GLOBAL SINGLE-USE BIOREACTORS MARKET, BY TYPE OF MOLECULE
8.1 Monoclonal Antibodies (MABS)
8.2 Vaccines
8.3 Stem Cells
8.4 Gene-Modified Cells
8.5 Other Molecules

9 GLOBAL SINGLE-USE BIOREACTORS MARKET, BY TYPE
9.1 Stirred-Tank Single Use Bioreactor
9.2 Wave-Induced Single Use Bioreactor
9.3 Bubble-Column Single Use Bioreactor
9.4 Other Single Use Bioreactor

10 GLOBAL SINGLE-USE BIOREACTORSMARKET, BY GEOGRAPHY
10.1 Overview
10.2 North AmericaRegional Market Estimates and Forecasts, 2012 - 2025
10.2.1 U.S.
10.2.2 Canada
10.2.3 Mexico
10.3 EuropeRegional Market Estimates and Forecasts, 2012 - 2025
10.3.1 Germany
10.3.2 U.K.
10.3.3 France
10.3.4 Rest of Europe
10.4 Asia PacificRegional Market Estimates and Forecasts, 2012 - 2025
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Rest of Asia Pacific
10.5 Latin AmericaRegional Market Estimates and Forecasts, 2012 - 2025
10.5.1 Brazil
10.5.2 Argentina
10.6 Rest of the WorldRegional Market Estimates and Forecasts, 2012 - 2025

11 GLOBAL SINGLE-USE BIOREACTORSMARKETCOMPETITIVE LANDSCAPE
11.1 Overview
11.2 Company Market Share
11.3 Vendor Landscape
11.4 Key Development Strategies

12 COMPANY PROFILES
12.1 Sartorius Stedim Biotech
12.1.1 Overview
12.1.2 Financial Performance
12.1.3 Product Outlook
12.1.4 Key Developments

12.2 Merck Millipore
12.2.1 Overview
12.2.2 Financial Performance
12.2.3 Product Outlook
12.2.4 Key Developments

12.3 GE Healthcare
12.3.1 Overview
12.3.2 Financial Performance
12.3.3 Product Outlook
12.3.4 Key Developments

12.4 Danaher
12.4.1 Overview
12.4.2 Financial Performance
12.4.3 Product Outlook
12.4.4 Key Developments

12.5 Thermo Fisher Scientific
12.5.1 Overview
12.5.2 Financial Performance
12.5.3 Product Outlook
12.5.4 Key Developments

12.6 Parker Hannifin
12.6.1 Overview
12.6.2 Financial Performance
12.6.3 Product Outlook
12.6.4 Key Developments

12.7 Applikon Biotechnology
12.7.1 Overview
12.7.2 Financial Performance
12.7.3 Product Outlook
12.7.4 Key Developments

12.8 Eppendorf
12.8.1 Overview
12.8.2 Financial Performance
12.8.3 Product Outlook
12.8.4 Key Developments

12.9 Cesco Bioengineering
12.9.1 Overview
12.9.2 Financial Performance
12.9.3 Product Outlook
12.9.4 Key Development

12.10 Cellexus
12.10.1 Overview
12.10.2 Financial Performance
12.10.3 Product Outlook
12.10.4 Key Development

12.11 Celltainer Biotech
12.11.1 Overview
12.11.2 Financial Performance
12.11.3 Product Outlook
12.11.4 Key Development

12.12 PBS Biotech
12.12.1 Overview
12.12.2 Financial Performance
12.12.3 Product Outlook
12.12.4 Key Development

12.13 Distek
12.13.1 Overview
12.13.2 Financial Performance
12.13.3 Product Outlook
12.13.4 Key Development

12.14 Solida Biotech
12.14.1 Overview
12.14.2 Financial Performance
12.14.3 Product Outlook
12.14.4 Key Development

12.15 Pierre Guerin
12.15.1 Overview
12.15.2 Financial Performance
12.15.3 Product Outlook
12.15.4 Key Development

13 Appendix
13.1 Related Reports